2 recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Recruiting 2 |
Follow Nucresiran: new trials by email Literature Review of Nucresiran trials Research Report on Nucresiran
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy Nucresiran, Vutrisiran - Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN | Phase 3 | Recruiting | Alnylam Pharmaceuticals | 125 | 2026-02-03 | 2026-10-08 |
| TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy Nucresiran, Sterile Normal Saline (0.9% NaCl) - Transthyretin Amyloidosis With Cardiomyopathy | Phase 3 | Recruiting | Alnylam Pharmaceuticals | 1750 | 2025-07-02 | 2026-10-20 |
Amyloidosis (2) · Cardiomyopathies (1) · Polyneuropathies (1)
Argentina (2) · Australia (2) · Brazil (2) · Canada (2) · France (2) · Germany (2) · Greece (2) · Ireland (2) · Italy (2) · Japan (2) · Malaysia (2) · Mexico (2) · Portugal (2) · South Korea (2) · Spain (2)
2025 (1)